Isomorphic Software – provider of the most advanced platform for building progressive web apps – announced a new skin (‘Obsidian’) included in Release 12.

With Release 12, developers AND end-users become highly-productive. It takes progressive web apps to the next level.”

— Charles Kendrick, CTO of Isomorphic Software

SAN FRANCISCO, CA, UNITED STATES, March 19, 2018 /EINPresswire.com/ — OK, I am just gonna say it: Enterprise web applications are boring. If, like me, you want to spice it up and build something a little edgier, look no further than Isomorphic Software's new Obsidian skin. Obsidian is like a cross between the Empire Strikes Back and a Prada suit: It's dark, mysterious, and incredibly hip.

Mirroring Isomorphic’s ‘Tahoe‘ skin, Obsidian is flat and modern, but the similarities end there. Obsidian is dark, dark black. It has hints of blue and grey to draw your eye to any web app's important features. Bright colored charts pop against the dark background. It truly is a thing of beauty.

Isomorphic Software's Release 12 will be available later this month and is a major upgrade for Isomorphic's SmartClient and Smart GWT technologies. Release 12 enables developers to build high-quality, high performance web apps faster; End-users to become even more productive; and it offers no-compromise UI – regardless of the device you choose (desktop, tablet or smartphone).

Isomorphic Software is based in San Francisco and has over a decade of industry leadership, providing technology platforms for building enterprise web applications. Organizations around the world use the SmartClient Platform, including Cisco, Boeing, Toyota, Philips, and Genentech.

PUNE, INDIA, March 20, 2018 /EINPresswire.com/ — WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Partnerships, Licensing, Investments and M&A Deals and Trends for December 2017 in Pharmaceuticals”

Pharmaceuticals – Partnerships, Licensing, Investments and M&A

Overview

"Partnerships, Licensing, Investments and M&A Deals and Trends for December 2017 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in December 2017.

The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

The pharmaceutical and healthcare industry reported a decrease in the number of deals and deal values in December 2017. The industry reported 375 deals worth USD21 billion in December 2017, compared to 403 deals worth USD27.5 billion in November 2017. The oncology therapeutics market remained at the top in deal activity in December 2017 with 124 deals.

Pharmaceuticals Sector Investments and M&A Major Outlook

Analysis of the market trends for the pharmaceutical industry in the global arena.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Pharmaceuticals Sector Investments and M&A – Competitive Analysis

Key players are making innovative developments in Pharmaceuticals Sector Investments and M&A. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

A nonprofit corporation opposed to assisted suicide and euthanasia, worldwide

HARTFORD, CONNECTICUT , USA, March 19, 2018 /EINPresswire.com/ — Dore: “The bill applies to people with years or decades to live.”

“The bill is sold as assuring individual choice and control. The bill is instead stacked against the individual and a recipe for elder abuse.”

Hartford, CT – Attorney Margaret Dore, president of Choice is an Illusion, which has fought assisted suicide/euthanasia legalization efforts in many states and now Connecticut, made the following statement in connection with tomorrow’s legislative hearing on a bill seeking to legalize assisted suicide and euthanasia in that state. (HB 5417, Public Health Committee Hearing, LOB, Room 2C, Tuesday, 03/20/18, 11:00 am).

“There is a bill pending before the Connecticut General Assembly, which seeks to legalize physician-assisted suicide, assisted suicide and euthanasia as those terms are traditionally defined,” said Dore. “The bill describes these practices as ‘aid in dying,’ but there is no requirement that patients be dying. Indeed, ‘eligible’ persons may have years or decades, to live.”

Dore said, "The bill is sold as assuring individual choice and control. The bill is instead stacked against the individual and a recipe for elder abuse.” Dore elaborated, “This is especially an issue for people with money, meaning the middle class and above. In short, their heirs and other predators want their money.”

“The easiest thing to see is a complete lack of oversight at the death,” said Dore. “ No doctor, not even a witness, is required to be present when the lethal is administered. If the patient objected, or even struggled, who would know? The bill creates the perfect crime.”

Dore said, “The bill seeks to legalize assisted suicide and euthanasia for people who are ‘terminal,’ which is defined as a doctor’s prediction of less than six months to live. In real life, such persons can have years, even decades, to live.”

“Treatment can lead to recovery,” said Dore. “I have a friend who was talked out of using Oregon’s assisted suicide law in 2000. Her doctor convinced her to be treated for cancer instead. She is still alive today, seventeen years later.”

“Doctors can also be wrong about life expectancy, sometimes way wrong," said Dore. "This is due to actual mistakes and the fact that predicting life expectancy is not an exact science. A few years ago, I was met at the airport by a man who at age 18 had been diagnosed with ALS and given 3 to 5 years to live, at which time he was predicted to die by paralysis. His diagnosis had been confirmed by the Mayo Clinic. When he met me at the airport, he was 74 years old. The disease
progression had stopped on its own.”

Dore said, “I have had two clients whose fathers signed up for the lethal dose. In the first case, one side of the family wanted the father to take the lethal dose, while the other did not. He spent the last months of his life caught in the middle and traumatized over whether or not he should kill himself. My client, his adult child, was also traumatized. The father did not take the lethal dose and died a natural death.”

“In the other case,” said Dore, “it's not clear that administration of the lethal dose was voluntary. A man who was present told my client that his father had refused to take the lethal dose when it was delivered (“You’re not killing me. I’m going to bed”), but then took it the next night when he was high on alcohol. The man who told this to my client subsequently recanted. My client did not want to pursue the matter further.”

“If the Connecticut bill becomes law, there will be new lethal paths of elder abuse, which will be legally sanctioned," said Dore. "People with years, even decades to live, will be encouraged to throw away their lives. Even if you like the concept of assisted suicide and euthanasia, the proposed bill has it all wrong.”

Wiseguyreports.Com Adds “Hookah -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023” To Its Research Database

A hookah is a smoking device with a single or multi-stemmed instrument for vaporizing and smoking flavored tobacco, called shisha, whose vapor or smoke is passed through a water basin—often glass-based—before inhalation. There are two kinds of hookahs: the traditional ones that you see in hookah bars and newer hookah pens (e-hookahs). Health risks of smoking hookah include exposure to toxic chemicals that are not filtered out by the water and risk of infectious disease when hookahs are shared.

The Asia-Pacific Hookah market will reach xxx Million USD in 2018 and CAGR xx% 2018-2023. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Hookah by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.

Wiseguyreports.Com Adds “Yoga Mat -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023” To Its Research Database

Yoga mats are specially fabricated mats used as an aid during the practice of yoga to prevent hands and feet slipping during practice. They are mainly used both for home use and for yoga studios.

The Asia-Pacific Yoga Mat market will reach xxx Million USD in 2018 and CAGR xx% 2018-2023. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Yoga Mat by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.

BONITA SPRINGS, FLORIDA, UNITED STATES, March 19, 2018 /EINPresswire.com/ — Denise Lescano is recognized as a psychic medium, medical intuitive, intuitive consultant, healer, teacher and author. She stresses that all mediums are psychics, but that not all psychics are mediums. She has a rare gift for communicating with persons who are no longer living on this plane; a gift that ranks her as one of the world’s leading experts on afterlife communication.

Denise runs a company that incorporates all her work in media, publishing, psychic consulting services, and her volunteer efforts, known collectively as Spirit Works, Inc.. Denise and her incredible readings were also featured in Josie Varga’s acclaimed book Visits from Heaven.

Denise has been tested and endorsed by several authorities, and was hand-selected to participate in a data collection scientific research project that is bridging the gap between science and spirituality. The PhDs running the Afterlife Data project monitor her readings, track evidence, and affirm facts about death, dying, and proof of heaven. The scientists (and science doesn’t lie) rate Denise’s accuracy a staggering 88 to 92 percent.

It’s this breadth of talent and level of competence, plus the type of professionals that Denise chooses to support as a medium, that make her nearly peerless. She truly is, as the title of her 2010 book says, The Messenger–and she has some very interesting and significant communications to relay.

Denise is the FIRST and ONLY Psychic Medium to work directly with Grief and Addiction recovery counselors in grief and addiction recovery support groups. Since 2005, she’s used her abilities for very noble purposes. She worked with The Collier County State Attorney’s Office, Grief Counselors, Victim Advocacy Centers, non-profits like MADD and AA, Federal and local Law Enforcement authorities and the Military. She consults on investigations and helps solve crimes, particularly missing persons or homicides. Denise also brings closure to families who lost a loved one to suicide, sudden or accidental death. She pinpoints the source of disease and provides detailed information for doctors. In recovery groups, Denise communicates with the deceased, with a counselor present, so the information received can be processed and assimilated into the treatment.

Denise is also often hired to resolve hauntings and offers readings at her Office in Naples, FL, or by phone or Skype. Sometimes it’s traditional psychic readings—like what might be in store for love, family and career. She has a BS in Communications with a minor in the Social Sciences and world religions. This knowledge, along with her intuitive knowing, make her a dynamic media personality, so be sure to tune in.

She will discuss the Psychic and Medium Certification training she created (and teaches) in the US and in Japan, and her participation in the Afterlife Data Project, called “Voices Across the Veil”–a scientific research study she has been involved in for the last 3 years. Denise believes science has long looked upon life after death with skepticism. Finally, change is happening, and she is enthused to be one of the ground-breakers.

CUTV News will feature Denise Lescano in an Interview with Jim Masters on Wednesday March 21 at 12:00 Noon EST.

MINOT, MAINE, UNITED STATES, March 19, 2018 /EINPresswire.com/ — Jessica Montañez’s goal has always been to deepen and strengthen the connection between animals and people.

Montañez is an animal communicator, healer, spiritual and holistic wellness coach and the founder of The Holistic Being, where she offers holistic and spiritual well-being services for animals and their people.

“This work is about giving the animal a voice,” says Montañez. “For me, it’s a way to help animals live the best possible life. If their owners and their handlers and their veterinarians can really understand them, their life is going to be better. You want to be able to understand them and honor them the same way you would a family member.”

According to Montañez, communicating with animals is something we do naturally when we're children. It's not until we learn how to talk that we discover animals cannot talk back to us. Montañez discovered her gift at an early age when a local equine veterinarian recognized her intuitive ability to share the thoughts, emotions, energy, and physical sensations that the horses were experiencing. Over the years she continued to hone those skills and pursue training in various holistic healing modalities.

Montañez works remotely with animals–dogs, cats, horses, birds and even a few reptiles–all over the world, communicating telepathically with the animal.

“I do my work through meditation, so it's dialing in and being on the same channel with the animal, so I can receive messages, sensations and imagery,” explains Montañez. “I explain in great detail everything that I see and capture. It’s like reading a really beautiful story about your animal while also getting the answers you need to understand your animal companion on a deeper level, including gaining clarity on their behaviors, desires, and symptoms.”

And because animals are natural sponges and empaths, they are our greatest teachers. They can show us what's going on inside of us through their behaviors and actions.”

“I’m proud of the understanding I can bring,” says Montañez. “For me, what keeps me doing this work is knowing the difference it's made in their lives and in their pets' lives.”

CUTV News Radio will feature Jessica Montañez in an interview with Doug Llewelyn on March 20th at 11am EST.

PUNE , INDIA, March 19, 2018 /EINPresswire.com/ — SummaryThe report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Airway Management pipeline products.

Scope– Extensive coverage of the Airway Management under development – The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities – The report reviews the major players involved in the development of Airway Management and list all their pipeline projects – The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage – The report provides key clinical trial data of ongoing trials specific to pipeline products – Recent developments in the segment / industry

PUNE , INDIA, March 19, 2018 /EINPresswire.com/ — SummaryFractures are simply a break in a bone caused by forces that exceed the strength of the osseous tissue in the bone. Signs and symptoms of a fracture include swelling or bruising over a bone, deformity of an arm or leg, loss of function in the injured area and in compound fractures, bone protruding from the skin.

Report HighlightsPharmaceutical and Healthcare latest pipeline guide Bone Fracture – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Bone Fracture (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Fracture (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Bone Fracture and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 7, 1, 12 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

Bone Fracture (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

PUNE , INDIA, March 19, 2018 /EINPresswire.com/ — SummaryAchondroplasia is a bone growth disorder that causes disproportionate dwarfism. This is caused by mutations in the FGFR3 gene. Symptoms include decreased muscle tone, apnea, hydrocephalus, short arms and legs, disproportionately large head compared to the body and kyphosis. Treatment includes growth hormones.

Report HighlightsPharmaceutical and Healthcare latest pipeline guide Achondroplasia – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Achondroplasia (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Achondroplasia (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Achondroplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 3 respectively.

Achondroplasia (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope– The pipeline guide provides a snapshot of the global therapeutic landscape of Achondroplasia (Musculoskeletal Disorders). – The pipeline guide reviews pipeline therapeutics for Achondroplasia (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. – The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. – The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. – The pipeline guide reviews key companies involved in Achondroplasia (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects. – The pipeline guide evaluates Achondroplasia (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. – The pipeline guide encapsulates all the dormant and discontinued pipeline projects. – The pipeline guide reviews latest news related to pipeline therapeutics for Achondroplasia (Musculoskeletal Disorders)

Reasons to buy– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. – Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. – Find and recognize significant and varied types of therapeutics under development for Achondroplasia (Musculoskeletal Disorders). – Classify potential new clients or partners in the target demographic. – Develop tactical initiatives by understanding the focus areas of leading companies. – Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. – Formulate corrective measures for pipeline projects by understanding Achondroplasia (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics. – Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. – Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.